- Intellia Therapeutics - WikipediaBiotechnology companyIntellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, ...See more on Wikipedia
Intellia Therapeutics Announces First Patient Dosed in the HAELO …
Jan 22, 2025 · Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its …
Intellia Announces First Clinical Evidence from Ongoing Phase 1 …
Nov 16, 2024 · Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. Development and …
- bing.com › videosWatch full video
Intellia doses first subject in trial of NTLA-2002 for hereditary
Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary …
Intellia Presents Positive Results from the Phase 2 Study
Oct 24, 2024 · Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use …
Our Science - Intellia Therapeutics
In the future, Intellia hopes to use its CRISPR technology to address a variety of severe, life-threatening diseases. HOW DOES CRISPR WORK? The CRISPR/Cas9 system works by targeting a specific location in the DNA to …
Intellia links in vivo CRISPR therapy to 81% drop in HAE …
Oct 24, 2024 · Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction...
Intellia Announces Positive Clinical Proof-of-Concept Data
Jun 25, 2024 · Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s …
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 ...
Nov 9, 2020 · Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease …
Full-Spectrum Approach - Intellia Therapeutics
LNPs are fat-based molecules that are the basis of Intellia’s CRISPR/Cas9 delivery platform. In Intellia’s experimental treatments, an LNP delivers to its target gene a simple, two-part genome editing system: the messenger RNA …
Related searches for Intellia Therapeutics CRISPR
